BR0310100A - métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto - Google Patents

métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto

Info

Publication number
BR0310100A
BR0310100A BRPI0310100-2A BR0310100A BR0310100A BR 0310100 A BR0310100 A BR 0310100A BR 0310100 A BR0310100 A BR 0310100A BR 0310100 A BR0310100 A BR 0310100A
Authority
BR
Brazil
Prior art keywords
treat
prevent
organ
tissue
reperfusion injury
Prior art date
Application number
BRPI0310100-2A
Other languages
English (en)
Inventor
Charles L Bisgaier
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of BR0310100A publication Critical patent/BR0310100A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"MéTODOS PARA TRATAR, PREVENIR OU REDUZIR A LESãO DE REPERFUSãO ISQUêMICA EM UM TECIDO OU óRGãO, E PARA PREVENIR OU TRATAR DE UMA CONDIçãO ASSOCIADA COM A PRIVAçãO DE OXIGêNIO, SEGUIDA POR SUPRIMENTO DE OXIGêNIO AUMENTADO A UM TECIDO OU óRGãO EM NECESSIDADE DISTO". A invenção provê métodos e composições para tratar ou prevenir a lesão de reperfusão isquêmica. Os métodos da presente invenção compreendem a administração de composições que compreendem as apolipoproteínas, lecitina colesterol aciltransferase ou paraoxonase, para tratar, reduzir ou prevenir lesão de reperfusão isquêmica.
BRPI0310100-2A 2002-05-17 2003-05-16 métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto BR0310100A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38165302P 2002-05-17 2002-05-17
US40547802P 2002-08-23 2002-08-23
PCT/US2003/015469 WO2003097696A1 (en) 2002-05-17 2003-05-16 Methods and copositions for the treatment of ischemic reperfusion

Publications (1)

Publication Number Publication Date
BR0310100A true BR0310100A (pt) 2007-04-27

Family

ID=29553542

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0310100-2A BR0310100A (pt) 2002-05-17 2003-05-16 métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto

Country Status (13)

Country Link
US (1) US20040038891A1 (pt)
EP (1) EP1556413A4 (pt)
JP (1) JP2006502976A (pt)
KR (1) KR20050010006A (pt)
CN (1) CN1668645A (pt)
AU (1) AU2003234625A1 (pt)
BR (1) BR0310100A (pt)
CA (1) CA2485989A1 (pt)
IL (1) IL165253A0 (pt)
MX (1) MXPA04011227A (pt)
NZ (1) NZ537006A (pt)
PL (1) PL374126A1 (pt)
WO (1) WO2003097696A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0310099A (pt) 2002-05-17 2007-03-20 Esperion Therapeutics Inc método para tratar dislipidemia ou uma doença associada com a dislipidemia
EP1545576A2 (en) * 2002-07-30 2005-06-29 Esperion Therapeutics Inc. Methods of using non-human animal apoliprotein a-i protein
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
CA2531279A1 (en) * 2003-07-28 2005-02-10 Dr. Reddy's Laboratories, Inc. Treatment and preventi0n of cardiovascular events
PE20050438A1 (es) * 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
JP4681455B2 (ja) * 2004-02-04 2011-05-11 田辺三菱製薬株式会社 パラオキソナーゼ含有製剤
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
WO2006107107A1 (ja) * 2005-04-01 2006-10-12 Fumitaka Ohsuzu リン脂質小胞体を含む心筋保護剤および虚血・再潅流時の心筋障害を予防する方法
US20070116756A1 (en) * 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
WO2011006994A1 (en) 2009-07-16 2011-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Hdl comprising a therapeutic agent and use in therapy
AU2011207563B2 (en) 2010-01-19 2016-03-10 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
PL3178481T3 (pl) 2010-06-30 2019-07-31 Csl Limited Odtworzona formulacja lipoproteiny o wysokiej gęstości i sposób jej produkcji
BR112013004395A2 (pt) 2010-08-30 2019-09-24 Hoffmann La Roche tetranectina-apolipoproteína a-i, partículas de lipídio que a contém a sua utilização
SG191992A1 (en) 2011-01-19 2013-08-30 Univ Cincinnati Apolipoprotein aiv as an antidiabetic peptide
CN103747674B (zh) 2011-06-09 2016-06-15 生命线科学有限公司 器官/组织的活力的评价、维持和/或恢复
JP6207507B2 (ja) 2011-08-25 2017-10-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 短縮されたテトラネクチン−アポリポプロテインａ−ｉ融合タンパク質、それを含む脂質粒子、及びその使用
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
WO2013109342A1 (en) 2012-01-19 2013-07-25 University Of Cincinnati Method of treating diabetes using non-glycosylated apolipoprotein a-iv
US10232019B2 (en) 2012-07-25 2019-03-19 University Of Cincinnati Method of treating hyperglycemic disorders using apolipoprotein AIV
JP2015524808A (ja) 2012-07-25 2015-08-27 ユニバーシティ・オブ・シンシナティ アポリポタンパク質ａｉｖを用いたｉ型糖尿病の治療法
US9125943B2 (en) 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
US20140278468A1 (en) 2013-03-15 2014-09-18 I.D. Therapeutics Llc Apparatus and method for optimizing treatment using medication compliance patterns and glucose sensor
US10420337B2 (en) 2013-03-15 2019-09-24 Lifeline Scientific, Inc. Transporter with a glucose sensor for determining viability of an organ or tissue
WO2015023797A1 (en) 2013-08-13 2015-02-19 Northwestern University Lipophilic nanoparticles for drug delivery
US10413565B2 (en) 2014-04-30 2019-09-17 Northwestern University Nanostructures for modulating intercellular communication and uses thereof
EP3204499A4 (en) 2014-10-06 2018-04-25 Exicure, Inc. Anti-tnf compounds
WO2016085986A1 (en) * 2014-11-24 2016-06-02 Northwestern University High density lipoprptein nanoparticles for inflammation
US9617230B2 (en) 2014-12-22 2017-04-11 Farmington Pharma Development Creatine prodrugs, compositions and methods of use thereof
JP7168990B2 (ja) 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物
WO2018107685A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种治疗冠状动脉粥样硬化及其并发症的方法
US11389515B2 (en) 2016-12-15 2022-07-19 Talengen International Limited Method for mitigating heart disease
CN110494134A (zh) * 2017-03-31 2019-11-22 圣十字圣保罗医院教堂基金会 用于缺血相关损伤的预防/减少的他汀
CA3082184A1 (en) 2017-12-01 2019-06-06 Ultragenyx Pharmaceutical Inc. Creatine prodrugs, compositions and methods of use thereof
WO2022099574A1 (zh) * 2020-11-13 2022-05-19 兰州大学 哌唑嗪用于制备治疗和/或预防脑血管疾病药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2703893B2 (ja) * 1985-07-05 1998-01-26 ホワイトヘッド・インスティテュ−ト・フォ−・バイオメディカル・リサ−チ 外来遺伝子物質を発現する上皮細胞
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
JPH02231708A (ja) * 1989-03-06 1990-09-13 Fujitsu Ltd 半導体装置の位置合わせマーク検出方法及び装置
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
US5552267A (en) * 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
SE9203753D0 (sv) * 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US6258596B1 (en) * 1995-05-22 2001-07-10 Aventis Pharmaceuticals Products Inc. Variants of apolipoprotein A-I
US5843474A (en) * 1995-10-11 1998-12-01 Reverse Transport Licensing & Consulting, Inc. Method of dialysis treatment, and dialysis apparatus related thereto
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603303D0 (sv) * 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) * 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
AU2002214644A1 (en) * 2000-10-13 2002-04-22 University Of Cincinnati Methods for enhancing lysing of coagulated blood with apolipoprotein e2 phenotype
US20040266660A1 (en) * 2001-08-20 2004-12-30 Alphonse Hubsch Hdl for the treatment of stroke and other ischemic conditions

Also Published As

Publication number Publication date
NZ537006A (en) 2008-01-31
IL165253A0 (en) 2005-12-18
MXPA04011227A (es) 2005-01-25
JP2006502976A (ja) 2006-01-26
CA2485989A1 (en) 2003-11-27
EP1556413A4 (en) 2009-07-08
PL374126A1 (en) 2005-10-03
AU2003234625A1 (en) 2003-12-02
US20040038891A1 (en) 2004-02-26
CN1668645A (zh) 2005-09-14
WO2003097696A1 (en) 2003-11-27
KR20050010006A (ko) 2005-01-26
EP1556413A1 (en) 2005-07-27

Similar Documents

Publication Publication Date Title
BR0310100A (pt) métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto
BR0013122A (pt) Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina
BR0309623A (pt) Agentes que regulam. inibem ou modulam a atividade e/ou a expressão do fator de crescimento de tecido conjuntivo (ctgf) como um único meio de diminuir a pressão intraocular e tratar retinopatias glaucomatosas/neuropatias ópticas
BR0206639A (pt) Combinações de inibidor(es) da absorção do esterol com modificador(es) do sangue para o tratamento de condições vasculares
AR039416A1 (es) Un metodo para prevenir y/o tratar el rechazo cronico en un organo o un tejido transplantado
BRPI0502346A (pt) processo de tratamento cosmético para prevenir e/ou tratar as peles sensìveis e/ou secas, utilização de uma quantidade eficaz de pelo menos um microorganismo notadamente probiótico e/ou uma de suas frações e/ou um de seus metabólitos e composição cosméticas e/ou dermatológica
BR0208563A (pt) composições de n-acetilcisteìna e métodos para o tratamento e prevenção de toxidade de droga
BR0318269A (pt) composições, alvos, métodos e dispositivos para a terapia de distúrbios oculares e perioculares
BR0310099A (pt) método para tratar dislipidemia ou uma doença associada com a dislipidemia
PT998288E (pt) Composicoes contendo capsaicina ou analogos de capsaicina e um anestesico local
BRPI0410041A (pt) métodos para tratamento de dor de cabeça de sinusite
BR0206644A (pt) Combinações de inibidor(es) de absorção de esteróis com agente(s) cardiovascular(es) para o tratamento de condições vasculares
BR0312286A (pt) pró-medicamentos de 2' e 3' - nucleosìdeo modificado para tratamento de infecções por flaviviridae
CY1111471T1 (el) Μεθοδοι για τον καθαρισμο trans-(-)-δ9-τετραϋδροκανναβινολης και trans-(+)-δ9 τετραϋδροκανναβινολης
BR9815442A (pt) Liberação terapêutica dirigida de compostos de vitamina d
BR0307871A (pt) Proteìnas contendo domìnio de folistatina
BRPI0612119A2 (pt) tratamento de distúrbio auto-imunes com uma neuroxotina
ECSP034815A (es) "composiciones de timolol y de lipido hipotensivas y los metodos para utilizarlas"
BRPI0510761A (pt) métodos de tratar um paciente afligido com pelo menos uma enfermidade e de reduzir ou eliminar rugas
BRPI0414794A (pt) oxadiazolidinadionas substituìdas
UA99434C2 (ru) Применение производных алкилфосфолипидов со сниженной цитотоксичностью
BRPI0516134A (pt) neurotoxinas de clostridium para uso na cicatrização de tecidos
BR0315573A (pt) Método para tratar, prevenir, controlar e/ou modificar dor em um paciente e composição farmacêutica
BR0315314A (pt) Método para o tratamento ou prevenção de sintomas de vasomotores em um paciente com necessidade do mesmo
BRPI0408827A (pt) composições oftálmicas preservadas

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DAS PRIORIDADES REIVINDICADAS (US60/381653 E US60/405478) POR NAO ATENDEREM A DISPOSICAO PREVISTA NO ART.16 6O E 7O DA LPI.

B150 Others concerning applications: publication cancelled [chapter 15.30 patent gazette]

Free format text: ANULADA A PERDA DE PRIORIDADE(15.9) PUBLICADA NA RPI 2011 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2116 DE 26/07/2011.